Lung Cancer News and Research

Latest Lung Cancer News and Research

Seno completes PIONEER Pivotal Study of non-invasive Imagio breast imaging system

Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced today it has completed the final phase of the company's U.S.-based PIONEER Pivotal Study of the Imagio® breast imaging system.

1 Oct 2015

LDCT lung cancer screening does not lead to unnecessary treatment

Lung cancer screening programs that utilize standardized reporting and include cardiothoracic surgeons as part of a multidisciplinary team can successfully be adopted into clinical practice without an increase in surgical intervention for non-cancerous disease, according to an article in the October 2015 issue of The Annals of Thoracic Surgery.

1 Oct 2015

Patients with advanced lung cancer receive more than recommended number of radiation therapy

Almost half of patients with advanced lung cancer receive more than the recommended number of radiation treatments to reduce their pain, according to a new study published in the Journal of the National Cancer Institute.

1 Oct 2015

Orlando Health gets Overall 3 Star Rating for bypass surgery and lobectomy

Orlando Health received an Overall 3 Star Rating from The Society of Thoracic Surgeons for quality care provided to patients undergoing bypass surgery and lobectomy for lung cancer.

30 Sep 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

Boehringer Ingelheim announced today results of a new European survey investigating therapy goals, prescribing habits and decision-making criteria of physicians treating patients with advanced lung cancer with adenocarcinoma histology after first-line chemotherapy.

29 Sep 2015

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.

From EKF Diagnostics 29 Sep 2015

New targeted therapy shows promise against small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently only diagnosed when it has spread to other parts of the body (metastasised). Five-year survival rates in SCLC, which accounts for about 14% of all lung cancers, are very low, at only six percent. But today US researchers will present two novel findings with important implications for treatment at the 2015 European Cancer Congress.

29 Sep 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour tissue as a sample. The test identifies 42 mutations in the epidermal growth factor receptor (EGFR) gene, the most of any In-vitro Diagnostic (IVD) on the market, and can also be used as an aid in selecting eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI).

From Roche Sequencing and Life Science 28 Sep 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

$Atezolizumab may change treatment strategies for refractory lung cancer patients$

Atezolizumab may change treatment strategies for refractory lung cancer patients

Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck's comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria.

28 Sep 2015

Nivolumab drug improves survival for non-SQ NSCLC patients

Patients with a type of lung cancer called non-squamous non-small cell lung cancer (non-SQ NSCLC) have limited treatment options and a dismal prognosis once their disease has advanced and initial treatment with platinum-based chemotherapy has failed. Second-line treatment is usually with another chemotherapy drug, such as docetaxel or pemetrexed.

28 Sep 2015

Portuguese researchers find significant differences between smokers and non-smokers who develop NSCLC

Tobacco smoke is known to be the main risk factor for non-small cell lung cancer (NSCLC), although non-smokers can get it too. The incidence among non-smokers is increasing in many countries. Now a group of Portuguese researchers has found significant differences in clinical particularities and survival between smokers and non-smokers who develop NSCLC.

28 Sep 2015

American College of Chest Physicians releases new clinical guidelines on EBUS-guided TBNA

The American College of Chest Physicians announced the release of new clinical guidelines on endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA). The guideline, which applies to a common bronchoscopic test, contains 12 recommendations including best practices related to patient factors and procedural aspects.

26 Sep 2015

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Comparisons of cancer patients' survival and care in Europe up to 2007 show that although more patients are surviving for at least five years after diagnosis, there are large variations between countries, which are particularly significant in cancers of the blood.

26 Sep 2015

Smokers who have COPD may face increased risk of getting small cell lung cancer

Smokers who have chronic obstructive pulmonary disorder (COPD) may face nearly twice the risk of getting small cell lung cancer (SCLC)--the deadliest form of lung cancer--than smokers who don't have COPD, according to a large worldwide study led by researchers at the Harvard T.H. Chan School of Public Health.

26 Sep 2015

Lung Cancer News and Research

Latest Lung Cancer News and Research

Seno completes PIONEER Pivotal Study of non-invasive Imagio breast imaging system

LDCT lung cancer screening does not lead to unnecessary treatment

Patients with advanced lung cancer receive more than recommended number of radiation therapy

Orlando Health gets Overall 3 Star Rating for bypass surgery and lobectomy

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

New targeted therapy shows promise against small cell lung cancer

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Atezolizumab may change treatment strategies for refractory lung cancer patients

Nivolumab drug improves survival for non-SQ NSCLC patients

Portuguese researchers find significant differences between smokers and non-smokers who develop NSCLC

American College of Chest Physicians releases new clinical guidelines on EBUS-guided TBNA

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Smokers who have COPD may face increased risk of getting small cell lung cancer

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in